Open an account

IQVIA Holdings

IQV · NYSE

$267.85+$1.97 (+0.74%)TodayMarket closed ·
Prev close $265.88

About IQV

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 93,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

Employees
93,000
Headquarters
Durham, North Carolina
Listed
May 9, 2013
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
ir.iqvia.com

IQV key statistics

Market cap
44.09B
Price-earnings ratio
33.03
Dividend yield
—
Average volume
1.28M
Volume
1.69M
Open price
$269.20
High today
$272.08
Low today
$263.28
52 Week high
$277.40
52 Week low
$154.50

IQVIA Holdings (IQV) at a glance

As of Oct 20, 2026, IQVIA Holdings (IQV) shares are priced at $267.85, giving the company a market cap of 44.09B and a price-to-earnings ratio of 33.03.

Today the stock has traded between $263.28 and $272.08. The current price is 1.7% above the day's low and 1.6% below its high.

Volume so far is 1.69M shares, above the average of 1.28M shares a day.

Over the past year IQVIA Holdings has ranged from $154.50 to $277.40, and now sits 92% of the way up that range.

IQVIA Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $3.15 per share against an estimate of $3.06.

The average analyst price target is $293.83, 9.7% above the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 16 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 22 analystsAvg $293.83
Low
$252.50
Now
$267.85
High
$362.25

IQV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 1.4% on average.

  1. Q3 FY24: reported $2.84 per share against an estimate of $2.84
  2. Q4 FY24: reported $3.12 per share against an estimate of $3.14
  3. Q1 FY25: reported $2.70 per share against an estimate of $2.66
  4. Q2 FY25: reported $2.81 per share against an estimate of $2.80
  5. Q3 FY25: reported $3.00 per share against an estimate of $3.00
  6. Q4 FY25: reported $3.42 per share against an estimate of $3.43
  7. Q1 FY26: reported $2.90 per share against an estimate of $2.85
  8. Q2 FY26: reported $3.15 per share against an estimate of $3.06

IQV news

  • Press releaseGlobe Newswire

    The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape

  • Press releaseBusiness Wire

    IQVIA Selects Veeva Clinical Operations Applications

  • Press releaseBusiness Wire

    IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

  • Press releaseBusiness Wire

    IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

  • Press releaseBusiness Wire

    IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

  • Press releaseBusiness Wire

    IQVIA Announces Pricing of Senior Notes

  • Press releaseBusiness Wire

    IQVIA Announces Offering of Senior Notes

  • Press releaseBusiness Wire

    IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

Similar companies

Companies in the same industry as IQVIA Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.